News | Cardiovascular Clinical Studies | May 20, 2024

Geisinger Enrolls First Patient in Amyloid Cardiomyopathy Trial

Cardiologist Brendan Carry, MD, and a team of Geisinger Health physicians have enrolled the first patient in the U.S. into a cardiac amyloidosis trial. The phase 3, randomized, double-blind, placebo-controlled study will evaluates the safety and effectiveness of amyloid deplete ALXN2220 in participants with transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM).

Cardiologist Brendan Carry, MD, and a team of Geisinger Medical Center physicians have enrolled the first patient in the U.S. into a cardiac amyloidosis trial. Image courtesy: Geisinger Medical Center/Mark Dastrup

Cardiologist Brendan Carry, MD, and a team of Geisinger Medical Center physicians based in Danville, PA, have enrolled the first patient in the U.S. into a cardiac amyloidosis trial. The phase 3, randomized, double-blind, placebo-controlled study will evaluates the safety and effectiveness of amyloid deplete ALXN2220 in participants with transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM). Image courtesy: Geisinger Medical Center/Mark Dastrup


May 20, 2024 — Cardiologist Brendan Carry, MD, and a team of Danville, PA-based Geisinger Medical Center physicians have enrolled the first patient in the U.S. into a cardiac amyloidosis trial. The team is also the first to in the U.S. to screen for the trial.

“If a patient qualifies for the clinical trial, it will allow us to provide a treatment option when they receive an amyloidosis diagnosis without having to travel outside of the region for care,” said Carry. “Geisinger is at the forefront of research and technological advancements that allow for better patient outcomes and improvements in their quality of life.”

Cardiac amyloidosis is caused by protein buildup between the muscle cells of the heart, increasing the thickness of the heart. As these proteins build up, the heart becomes thicker and struggles to pump blood. Over time as the heart thickens, heart failure develops.

Patients with amyloidosis can inherit it from their parents or develop the condition on their own. Signs include common heart failure symptoms, such as swelling in the extremities, increased shortness of breath and weight gain. Patients may also have neuropathy symptoms, weakness, difficulty walking, tingling or numbness in their limbs, a decrease in blood pressure when adjusting positions and carpal tunnel syndrome.

The trial is a phase 3, randomized, double-blind, placebo-controlled study that evaluates the safety and effectiveness of amyloid deplete ALXN2220 in participants with transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM).

To be considered for the trial, patients must be between the ages of 18 to 90, have a confirmed diagnosis of ATTR-CM with transthyretin that is either wild-type TTR or a variant TR genotype, and have not received prior treatment with an ATTR amyloid depleter.

This clinical trial is sponsored by Alexion Pharmaceuticals Inc.

For more information: www.geisinger.org


Related Content

News | Heart Failure

Heart failure is a rapidly growing public health issue that can be difficult to manage on a global scale. But there are ...

Home October 02, 2024
Home
News | Heart Failure

Sept. 30, 2024 — Cytokinetics, Inc. recently announced that additional analyses synthesizing data from SEQUOIA-HCM ...

Home October 02, 2024
Home
News | Heart Failure

Sept. 18, 2024 – Astellas Pharma Inc. recently announced that Digitiva, a non-invasive digital health solution for heart ...

Home September 19, 2024
Home
News | Heart Failure

Aug. 21, 2024 — The incidence rate of heart failure was 2- to 3-fold higher among American Indian populations than rates ...

Home August 21, 2024
Home
News | Heart Failure

July 31, 2024 — A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & ...

Home July 31, 2024
Home
News | Heart Failure

July 30, 2024 — Patients with congestive heart failure (CHF) having a compromised blood supply, are at greater risk of ...

Home July 30, 2024
Home
News | Heart Failure

July 29, 2024 — When it comes to treating cardiac arrest, acting quickly can mean the difference between life and death ...

Home July 29, 2024
Home
News | Heart Failure

June 27, 2024 — The human body has sophisticated defenses against the deposition of calcium minerals that stiffen heart ...

Home June 27, 2024
Home
News | Heart Failure

June 24, 2024 — Endotronix, Inc., a privately held company dedicated to advancing the treatment of heart failure (HF) at ...

Home June 24, 2024
Home
News | Heart Failure

June 18, 2024 — As we commemorate Juneteenth 2024, JACC, the flagship journal of the American College of Cardiology, has ...

Home June 18, 2024
Home
Subscribe Now